Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label safety study of 1.25 mg teduglutide formulation in Japanese pediatric short bowel syndrome patients dependent on parenteral support
2022-003572-16Phase 3
- Sponsor
- Takeda
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by Takeda. Primary endpoint: Number of participants with treatment-emergent adverse events.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2022-003572-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003572-16.